Eplerenone, a selective aldosterone receptor antagonist, was shown to attenuate the morbidity and mortality of patients with acute MI (115), and is being analysed to reduce PAI-1 levels in aldosterone-induced MI in a randomised control study (116). This evidence concerns the gene SERPINE1 and myocardial infarction.